HIMS•benzinga•December 19, 2024 at 02:48 PM

FDA Clarifies Policies For Compounders As National GLP-1 Supply Begins To Stabilize; Does Not Intend To Take Action Against Compounders For Violations Of FD&C Act Arising From Conditions That Depend On Tirzepatide Injection

No summary available.

Read the full article from the original source for complete details and context.

Article published on December 19, 2024 by benzinga